Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on BioNano Genomics (NASDAQ:BNGO) Inc on Wednesday, setting a price target of $15, which is approximately 91.08% above the present share price of $7.85.
DeGeeter expects BioNano Genomics Inc to post earnings per share (EPS) of -$0.06 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in BioNano Genomics, with an average price target of $14.33.
The analysts price targets range from a high of $15 to a low of $14.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $3.99 million and a net profit of -$11.13 million. The company's market cap is $2.19 billion.
According to TipRanks.com, Oppenheimer analyst Kevin DeGeeter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 51.0% and a 51.94% success rate.
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.